Comparison of effect characteristics between Rapid-Acting Insulin Analogues in hospitalized patients with type 1 and type 2 diabetes.
Not Applicable
- Conditions
- Type 1 and type 2 diabetes
- Registration Number
- JPRN-UMIN000042039
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who fall under any of the following will not be included in this study. 1) Patients with severe ketosis, diabetic coma or precoma 2) Patients with severe infections, before and after surgery, and with serious external injury 3) Patients with severe renal dysfunction or end-stage renal disease on dialysis 4) Patients judged by the attending physician to be inappropriate for this study due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the effects between Humalog and URLi, Fiasp by measuring blood glucose 10 times a day and calculating the AUC (trapezoidal method) for the increase in blood glucose from before breakfast.
- Secondary Outcome Measures
Name Time Method (1) Daily blood glucose fluctuation by AUC (trapezoidal method) of each insulin by CGM (Continuous Blood Glucose Monitoring Device) (2) Evaluation of endogenous insulin secretion by blood sampling of C-peptide 10 times a day (conducted only for type 2 diabetic patients) (3) Number of occurrences of hypoglycemia (4) Changes in mean blood glucose level on CGM (5) Changes in blood glucose SDlog on CGM (6) Comparison of the effects between URLi and Fiasp by measuring blood glucose 10 times a day and calculating the AUC (trapezoidal method) for the increase in blood glucose from before breakfast. (7) Comparison of the effects between URLi and Fiasp by CGM and calculating the AUC (trapezoidal method) for the increase in blood glucose from before breakfast.